Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites

Production of glycoconjugate vaccines involves the chemical conjugation of glycans to an immunogenic carrier protein such as Cross-Reactive-Material-197 (CRM(197)). Instead of using glycans from natural sources recent vaccine development has been focusing on the use of synthetically defined minimal...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Sci Rep
Egile Nagusiak: Möginger, Uwe, Resemann, Anja, Martin, Christopher E., Parameswarappa, Sharavathi, Govindan, Subramanian, Wamhoff, Eike-Christian, Broecker, Felix, Suckau, Detlev, Pereira, Claney Lebev, Anish, Chakkumkal, Seeberger, Peter H., Kolarich, Daniel
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Nature Publishing Group 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4740906/
https://ncbi.nlm.nih.gov/pubmed/26841683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/srep20488
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak